- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00550589
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women
RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming cancer.
PURPOSE: This phase II trial is studying the side effects and how well topical cidofovir works in treating HIV-infected patients with high-grade squamous intraepithelial lesions of the skin near the anus.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To evaluate the safety and tolerability of topical cidofovir in HIV-infected patients with perianal high-grade squamous intraepithelial lesions (HSIL).
- To estimate the regression rate of perianal HSIL in patients treated with this regimen.
Secondary
- To determine the human papilloma virus (HPV) DNA types and HPV strain variants present in perianal HSIL and normal perianal tissue.
- To determine if clinical regression of perianal HSIL is associated with clearance of HPV DNA.
- To identify the HPV DNA types present in the anus and cervix and compare them with the HPV DNA present in the perianus in order to determine if the HPV types associated with the perianal lesions are the same as those infecting the anus and cervix.
- To determine if there are abnormally methylated genes in perianal HSIL compared with normal perianal tissue and if these genes are the same or different from those that have been previously identified in anal and cervical dysplasia.
- To determine whether methylated genes are changed after treatment with cidofovir.
- To characterize differences in gene expression in perianal HSIL compared with normal perianal tissue.
- To examine changes in gene expression in perianal HSIL after exposure to cidofovir using RNA microarray analysis and confirm results with real-time polymerase chain reaction.
- To correlate pretreatment CD4 count, viral load, lesion size, methylation pattern, and/or HPV type and strain with the clinical efficacy of topical cidofovir.
OUTLINE: This is a multicenter study.
Patients apply topical cidofovir to the perianus once daily on days 1-5. Patients undergo punch biopsy of pretreatment lesional biopsy sites on day 14. Beginning 2-4 weeks after biopsy, patients receive course 2 of cidofovir therapy. Subsequent treatment repeats every 14 days for up to 6 courses* in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients receive a total of 6 courses of study therapy.
Patients undergo collection of tumor and normal tissue for histopathological and molecular correlative studies. Punch biopsies are obtained at baseline, after the first course of therapy, and at 6 weeks after completion of therapy. Tissue samples are examined for histopathology, human papilloma virus (HPV)DNA typing, DNA methylation, and gene expression (via RNA microarray analysis and polymerase chain reaction).
After completion of study therapy, patients are followed at 6 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1793
- UCLA Clinical AIDS Research and Education (CARE) Center
-
San Francisco, California, United States, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02118
- Boston University Cancer Research Center
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
New York, New York, United States, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
New York, New York, United States, 10010
- Laser Surgery Care
-
-
Washington
-
Seattle, Washington, United States, 98101
- Benaroya Research Institute at Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed perianal high-grade squamous intraepithelial lesions (HSIL) within the past 12 weeks
- The perianal skin (i.e., perianus) is defined as extending radially 5 cm from the anal verge
- Lesions must cover a surface area of ≥ 3 square centimeters
- Lesions extending outside the perianus (e.g., vulvar lesions on the posterior perineum bordering the perianus) are allowed
Serologic documentation of HIV infection AND meets 1 of the following criteria:
- Has been on stable highly active anti-retroviral therapy (HAART) for ≥ 12 weeks prior to study entry
- Has a CD4 count of > 200/mm³ AND is not receiving anti-retroviral therapy OR is currently receiving a non-HAART* anti-retroviral regimen with no plans to initiate HAART within the next 12 weeks NOTE: * A non-HAART regimen is considered to be a therapy that does not include a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor
- No untreated invasive cancer of the lower genital tract
- No concurrent neoplasia requiring cytotoxic therapy
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Life expectancy ≥ 3 months
- Hemoglobin ≥ 8 g/dL
- ANC ≥ 1,000/mm³
- Platelet count ≥ 75,000/mm³
- Creatinine < 1.5 times upper limit of normal (ULN)
- Total or conjugated (direct) bilirubin ≤ 2.5 times ULN
- AST and ALT ≤ 3 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study therapy
- No acute, opportunistic infection other than oral thrush, yeast vaginitis, or genital herpes within the past 14 days
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior ablative or surgical treatment of perianal dysplasia
At least 4 weeks since prior topical treatment for perianal dysplasia
- If any prior treatment caused significant trauma to ther area, healing should occur prior to starting treatment
- More than 14 days since prior acute treatment for infection (other than for oral thrush, yeast vaginitis, or genital herpes) or other serious medical illness
- No concurrent corticosteroids other than replacement doses
- No other concurrent investigational drugs except IND-approved anti-retroviral agents
- No concurrent systemic cytotoxic chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cidofovir
1.0% topical cidofovir cream
|
1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle).
Subjects will receive up to 6 cycles of treatment.
formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
Evaluated at baseline and 6 weeks after treatment discontinuation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)
Time Frame: 6 weeks after treatment discontinuation
|
6 weeks after treatment discontinuation
|
|
Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0
Time Frame: Every 2 weeks on study, 6 weeks after treatment discontinuation
|
Number of study patients who had a serious adverse event
|
Every 2 weeks on study, 6 weeks after treatment discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Human Papilloma Virus (HPV) DNA Type in Perianal HSIL and Normal Perianal Tissue
Time Frame: Baseline
|
Number of patients with HPV16 at baseline in perianal HSIL and normal perianal tissue
|
Baseline
|
Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA
Time Frame: 6 weeks after treatment discontinuation
|
Number of patients who cleared HPV among those who had a complete or partial response
|
6 weeks after treatment discontinuation
|
Identification of HPV-DNA Types Present in the Anus
Time Frame: Baseline
|
Number of patients with HPV16 type present in the anus from anal swab or cytobrush at baseline
|
Baseline
|
Identification of Abnormally Methylated Genes in Perianal Dysplasia
Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
Identification of abnormally methylated genes in perianal dysplasia
|
Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin
Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
|
Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis
Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
Baseline, after cycle 1, and 6 weeks after treatment discontinuation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Elizabeth Stier, MD, Boston Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Uterine Cervical Diseases
- Uterine Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Anus Diseases
- Uterine Cervical Dysplasia
- Precancerous Conditions
- Anus Neoplasms
- Squamous Intraepithelial Lesions of the Cervix
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Cidofovir
Other Study ID Numbers
- AMC-046
- U01CA121947 (U.S. NIH Grant/Contract)
- CDR0000570720 (OTHER: NCI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Condition
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)TerminatedMetaplasia | Dysplasia | Pulmonary Precancerous ConditionUnited States
-
National Cancer Institute (NCI)CompletedNeoplasms | Precancerous ConditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Institutes of Health (NIH)CompletedPrecancerous ConditionsUnited States
-
Renmin Hospital of Wuhan UniversityCompleted
-
All India Institute of Medical Sciences, New DelhiCompletedPrecancerous ConditionsIndia
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
Clinical Trials on cidofovir
-
University of PennsylvaniaCompletedPrevention of Hair GrowthUnited States
-
National Cancer Institute (NCI)Completed
-
Mithra PharmaceuticalsCompletedUterine Cervical Neoplasms | Cervix Intraepithelial NeoplasiaBelgium
-
National Center for Research Resources (NCRR)Northwestern UniversityCompletedAcquired Immunodeficiency Syndrome | Cytomegalovirus Retinitis
-
Medical University of ViennaUniversity of ViennaCompletedAcute Renal Failure | Cytomegalovirus RetinitisAustria
-
M.D. Anderson Cancer CenterActive, not recruitingTransplantation InfectionUnited States
-
ChimerixCompletedCMVUnited States, Belgium, Canada
-
Hospital Universitari Vall d'Hebron Research InstituteUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownCervical Cancer | Precancerous ConditionFrance